Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...

Adalimumab trough levels of 4.0 mg/L or higher among patients with RA were linked to greater treatment response and ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set ...

The company will protect the branded anti-interleukin (IL)-12/23 biologic against sales erosion from pending biosimilars.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a ...

#Data provided for the iv. administration only. ADM: Adalimumab; AUC 0-∞: Area under the plasma concentration-time curve from time zero to infinity; CL/F: Apparent total clearance of the drug ...

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...

The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...

Blue Shield of California is bypassing traditional pharmacy benefit managers to offer a Humira (adalimumab)-referenced biosimilar named Idacio to patients at the lowest list price currently ...